Sridhar Ramaswamy Laboratory


Center for Cancer Research
Simches Research Center, CPZN-4206
185 Cambridge Street
Boston, MA 02114
phone: 617-643-3140
fax: 617-643 3170

About Sridhar Ramaswamy

Dr. Ramaswamy is Assistant Professor of Medicine at Harvard Medical School and Tucker Gosnell Investigator at the Massachusetts General Hospital. He is also a Member of the Dana-Farber / Harvard Cancer Center, Broad Institute of Harvard & MIT, and Harvard Stem Cell Institute. His translational research program broadly focuses on understanding the cancer genome in functional terms, to guide the development of new drugs and diagnostics. As a clinical sub-specialist in Medical Oncology, Dr. Ramaswamy cares for patients with advanced solid tumors and actively mentors MD and PhD students, house officers, and subspecialty fellows at the MGH and Harvard.

Dr. Ramaswamy was educated at Williams College and Boston University. He served as an Intern, Resident, and Chief Resident in Medicine at Columbia-Presbyterian Medical Center in New York City. In addition to subspecialty training in Medical Oncology and Hematology at Harvard Medical School, he completed advanced research fellowships at the National Institutes of Health (Immunology), the Dana-Farber Cancer Institute (Oncology), and the Whitehead Institute (Genetics) prior to his recruitment to the MGH Cancer Center in 2004. He has received numerous awards for his translational research program, most recently from the National Cancer Institute, the Howard Hughes Medical Institute, and the Sidney Kimmel Foundation. Dr. Ramaswamy is an elected Fellow of the American College of Physicians.


Our laboratory at the Massachusetts General Hospital Cancer Center focuses on discovery research in cancer patients. We investigate the molecular and cellular basis of metastasis, the predominant cause of cancer deaths, to guide the development of clinically effective cancer drugs and diagnostics. Our research currently encompasses three thematically-linked areas:

  1. Molecular profiling of human cancer to identify candidate therapeutic targets and diagnostic, prognostic, and predictive biomarkers for advanced malignancy
  2. Functional genomic approaches to define molecular programs underlying cancer cell invasion, metastasis, and drug resistance
  3. Development of new methods to reverse engineer tumor stromal populations for the ex vivo cultivation of human cancer cells, to enable molecular cancer genetics and pharmacology
We use DNA, transcriptional, and proteomic profiling tools to generate genome-wide views of human cancer; emerging methods in cell biology and tissue engineering to experimentally model cancer progression in vitro and in vivo; genetic and chemical probes and advanced cellular imaging to functionally study identified genes, pathways, and cell states; and computational biology and statistics for the in silico integration and analysis of this complex data stream.

Lab Personnel

Jeff Gentry, MS Bioinformatics Specialist
Ed Leon, MS Clinical Research Assistant
Raymond Wadlow, MD Research Fellow
Ben Wittner, PhD Research Fellow
Anita Wolfer, MD, PhD Research Fellow
Andrew Yee, MD Research Fellow

copyright © 2008 mgh